However,
Almost 12% americans used glp-1 new: Consequently,
Almost 12% americans used glp-1:
Almost 12% of Americans used GLP-1 drugs for weight loss. Furthermore, including about a fifth of women aged 50 to 64, according to a new Rand report.
The survey of a representative sample at the national level of 8,793 Americans, the researchers found that 11.8% used GLP-1 and 14% agonists say they are interested in consuming medicines. Meanwhile, 74% say they don’t plan to take medication.
Among those who used GLP-1 medications. In addition. Therefore, report about half that they have undergone nausea and about a third have diarrhea-the two most common side effects associated with drugs.
The report is the most recent. Meanwhile. Furthermore, most important survey to date that estimates the number of Americans who have used drugs that have revolutionized weight loss care. Therefore, The report describes the use of GLP-1 almost 12% americans used glp-1 new almost 12% americans used glp-1 drugs both by age and sex.
The use of Ozempic. Consequently. other GLP-1 drugs has increased sharply in recent years since studies have shown that drugs can help people significantly help with weight loss. Since 2020, the number of prescriptions for drugs has more than tripled.
Rand researchers interviewed participants in the American Life Panel Rand to ask the use of GLP-1 drugs. their experiences with side effects. The survey was carried out in April and May 2025.
The results show that women tend to use GLP-1 drugs at higher rates than men. although there is considerable variability in age groups.
The use of GLP-1 drugs is the most common in ages 50 to 64. with the highest rate of use found in women in the age group. Among these 65 and over, the use of GLP-1 drugs is a little higher for men than almost 12% americans used glp-1 new for women. Conversely. among those almost 12% americans used glp-1 between 30. 49 years old, women are more than twice as likely to have used a GLP-1 than their male peers.
The Panel Rand American Life is an investigation committee on probability samples of around 11. 000 active and regularly interviewed aged 12 and over. The panel was developed by Rand in 2006.
The report. “new drug loss drugs: use of GLP-1 agonists and side effects in the United States”, is available on www.rand.org. The authors of the report are Robert Bozick, Shannon Donofry and Katherine M. Rancaño.
The publication is the first of what is planned to be a series of brief reports which highlight the. descriptive results Topline of surveys carried out on the Panel Rand American Life.
The Division of Education and Labor Rand is devoted to improving education and expanding economic opportunities for research and analysis.
almost 12% americans used glp-1 new
Almost 12% americans used glp-1 new
Almost 12% americans used glp-1
Further reading: Improve the memory of the elderly thanks to a food supplement? Scientists envisage it! – ARS calls for vigilance – Have you exhausted your sun capital? A dermatologist explains how knowledge – Should France follow the British example to protect itself from the VRS? – unsuspected threats to the eyes.
Further reading: Six tips to limit your daily exposure to microplastics – IVF to three parents saves children in hereditary diseases, according to scientists – Should we succumb to invisible injections? – Implementation of non -regulated health facilities (PDS) – Chikungunya: 12 active transmission homes in France.
